Search Results

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

Annovis Bio Inc. today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap.

Annovis Bio Inc. today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap.

Azitra, Inc. today announced that management will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.

Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q1 2024.

EditCo Bio, Inc., a leader in genome engineering innovation, announced the expansion of its T-cell editing portfolio with the launch of Knockout CD8+ T-cell Pools.

INmune Bio Inc., a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th.

INmune Bio Inc. today confirmed the Phase II Alzheimer’s Disease clinical trial, AD02, is appropriately powered following a blinded sample size re-estimation using the trial’s primary endpoint, the Early Mild Alzheimer’s Cognitive Composite (EMACC).